Melanoma News and Research

Latest Melanoma News and Research

New streamlined method harnesses tumor-infiltrating lymphocytes to improve outcomes

Jamie K. Teer, Ph.D., assistant member of the Cancer Biology and Evolution Program at Moffitt Cancer Center, and colleagues have developed a new streamlined method to rapidly identify the genetic changes in small protein fragments unique to melanoma cancer cells.

26 Jun 2013

Sentinel lymph node biopsy for early breast cancer: an interview with Prof. Gordon Wishart, Anglia Ruskin University

Our current method, which is recommended by the Association of Breast Surgeons in the UK, involves the use of injections of blue dye and radioisotope to identify the first node(s) under the arm (axilla) called the sentinel nodes.

25 Jun 2013

Researchers test modified dendritic cells in patients with melanoma

In this issue of the Journal of Clinical Investigation, researchers led by Scott Pruitt at Duke University and Merck Research Laboratories report on a human clinical trial in which modified dendritic cells, a component of the immune system, were tested in patients with melanoma.

25 Jun 2013

Researchers report therapeutic strategy that appears to destroy drug-resistant melanomas

An advanced tumor is a complex ecosystem. Though derived from a single cell, it evolves as it grows until it contains several subspecies of cells that vary dramatically in their genetic traits and behaviors.

21 Jun 2013

Genetic process that promotes cervical cancer warns about anti-viral therapies in certain cases

A new understanding of the genetic process that can lead to cervical cancer may help improve diagnosis of potentially dangerous lesions for some women, and also raises a warning flag about the use of anti-viral therapies in certain cases - suggesting they could actually trigger the cancer they are trying to cure.

20 Jun 2013

OncoSec Medical completes enrollment in ImmunoPulse trial for metastatic melanoma patients

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced the completion of patient enrollment in a Phase II clinical trial of ImmunoPulse for metastatic melanoma patients.

18 Jun 2013

Texas passes legislation to prohibit minors under 18 from indoor tanning

Texas has joined California, Vermont, Oregon, and Nevada by passing legislation that prohibits minors under the age of 18 from indoor tanning. This announcement comes shortly after the U.S. Food and Drug Administration proposed stricter regulations on indoor tanning beds, as well as a strong recommendation against the use of tanning beds by minors under the age of 18.

18 Jun 2013

Non-invasive odor analysis: A valuable technique for early diagnosis of melanoma

According to new research from the Monell Center and collaborating institutions, odors from human skin cells can be used to identify melanoma, the deadliest form of skin cancer. In addition to detecting a unique odor signature associated with melanoma cells, the researchers also demonstrated that a nanotechnology-based sensor could reliably differentiate melanoma cells from normal skin cells.

14 Jun 2013

Tumor suppressor p53 inactivation and restoration: an interview with Dr. Xin Lu, Ludwig Institute for Cancer Research

Before we talk about p53, it is important to understand why cancer cells are a problem for the body. Cancer cells multiply recklessly, refuse to die and blithely metastasize to set up shop in places where they don’t belong.

12 Jun 2013

Studies demonstrate that combined therapy could destroy drug-resistant cells within melanoma tumor

Advanced metastatic melanoma is a disease that has proven difficult to eradicate. Despite the success of melanoma-targeting drugs, tumors inevitably become drug resistant and return, more aggressive than before. In the current issue of the journal Cancer Cell, however, researchers at The Wistar Institute describe how they increase the effectiveness of anti-melanoma drugs by combining anticancer therapies with diabetes drugs.

12 Jun 2013

OncoSec Medical signs Sponsored Research Agreement with ODU for melanoma study

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, signed a Sponsored Research Agreement with Old Dominion University and the Frank Reidy Research Center for Bioelectrics.

11 Jun 2013

Connecticut passes law that bans minors from using indoor tanning devices

Connecticut has sent a strong message to young people that indoor tanning salons can be dangerous to their health by passing a law that bans minors under the age of 17 years old from using indoor tanning devices. The law is based on significant scientific evidence that links indoor tanning to increased risk of developing melanoma and other forms of skin cancer.

11 Jun 2013

Inflection Biosciences signs license agreement with CNIO to develop kinase inhibitors for cancer treatment

Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced that it has entered into a license agreement with the Spanish National Cancer Research Centre (CNIO) for the exclusive, worldwide rights to develop and commercialise several novel kinase inhibitors for the treatment of cancer.

6 Jun 2013

Scientists develop first dual-action drug against melanoma skin cancer cells

Scientists are reporting development and successful lab tests on the first potential drug to pack a lethal one-two punch against melanoma skin cancer cells. Hit number one destroys cells in the main tumor, and the second hit blocks the spread of the cancer to other sites in the body, according to their report in the journal ACS Chemical Biology.

6 Jun 2013

Researchers demonstrate how modified citrus pectin works against cancer

A new review by researchers at the University of Maryland School of Medicine highlights a large body of published research demonstrating how modified citrus pectin, works against cancer.

4 Jun 2013

Cancer immunotherapy shows promise in treating patients with metastatic tumors

Cancer immunotherapy is showing promise in treating patients with a variety of advanced, metastatic tumors, as evidenced by two newly unveiled studies from Yale Cancer Center.

4 Jun 2013

Data from Nivolumab phase I study in patients with kidney cancer to be presented at ASCO 2013

Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center will present a poster on a phase I clinical trial of Nivolumab, a PD-1 receptor blocking antibody, being used in combination with other drugs in patients with metastatic renal cell carcinoma at the ASCO Annual Meeting on June 3, 2013.

4 Jun 2013

Amgen reports encouraging results from talimogene laherparepvec phase 3 study in patients with metastatic melanoma

Amgen today announced detailed results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).

3 Jun 2013

New drug shows promising results with manageable side effects for treating melanoma

Researchers from UCLA's Jonsson Comprehensive Cancer Center report that a new drug in preliminary tests has shown promising results with very manageable side effects for treating patients with melanoma, the deadliest form of skin cancer.

3 Jun 2013

Combination of ipilimumab and nivolumab drugs reduces tumor size in metastatic melanoma patients

The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).

3 Jun 2013

Melanoma News and Research

Latest Melanoma News and Research

New streamlined method harnesses tumor-infiltrating lymphocytes to improve outcomes

Sentinel lymph node biopsy for early breast cancer: an interview with Prof. Gordon Wishart, Anglia Ruskin University

Researchers test modified dendritic cells in patients with melanoma

Researchers report therapeutic strategy that appears to destroy drug-resistant melanomas

Genetic process that promotes cervical cancer warns about anti-viral therapies in certain cases

OncoSec Medical completes enrollment in ImmunoPulse trial for metastatic melanoma patients

Texas passes legislation to prohibit minors under 18 from indoor tanning

Non-invasive odor analysis: A valuable technique for early diagnosis of melanoma

Tumor suppressor p53 inactivation and restoration: an interview with Dr. Xin Lu, Ludwig Institute for Cancer Research

Studies demonstrate that combined therapy could destroy drug-resistant cells within melanoma tumor

OncoSec Medical signs Sponsored Research Agreement with ODU for melanoma study

Connecticut passes law that bans minors from using indoor tanning devices

Inflection Biosciences signs license agreement with CNIO to develop kinase inhibitors for cancer treatment

Scientists develop first dual-action drug against melanoma skin cancer cells

Researchers demonstrate how modified citrus pectin works against cancer

Cancer immunotherapy shows promise in treating patients with metastatic tumors

Data from Nivolumab phase I study in patients with kidney cancer to be presented at ASCO 2013

Amgen reports encouraging results from talimogene laherparepvec phase 3 study in patients with metastatic melanoma

New drug shows promising results with manageable side effects for treating melanoma

Combination of ipilimumab and nivolumab drugs reduces tumor size in metastatic melanoma patients

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Melanoma News and Research

Latest Melanoma News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in